Xiaoyang Mei
Psychiatric/Mental Health · Flushing, NYNPI 1871214676
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $50.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Alkermes, Inc.$1K
- Axsome Therapeutics, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $2K from 10 others
What the payments were for
- Food & beverage$10,74598%
- Education$2252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 35 | $1,892 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $1,754 |
| AbbVie | 28 | $1,561 |
| Alkermes, Inc. | 33 | $1,440 |
| Axsome Therapeutics, Inc. | 20 | $1,335 |
| Otsuka America Pharmaceutical, Inc. | 23 | $1,121 |
| E.r. Squibb & Sons, L.L.C. | 14 | $603 |
| Neurocrine Biosciences, Inc. | 3 | $283 |
| Idorsia Pharmaceuticals US Inc | 6 | $212 |
| Supernus Pharmaceuticals, Inc. | 2 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $137 |
| GSK | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $116 |
| Boehringer Ingelheim | 1 | $113 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $73 |
| Lundbeck LLC | 3 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,887
- VRAYLAR$1,141
- Auvelity$1,080
- CAPLYTA$1,072
- REXULTI$750
- UZEDY$722
- ARISTADA$480
- COBENFY$375
- INGREZZA$259
- Austedo XR$245
- NUCALA$125
- AUSTEDO$125
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- QELBREE$125
- QUVIVIQ$121
- ARISTADA INITIO$120
- Fanapt$116
- JARDIANCE$113
How this compares
$10,970 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 159 | $231,976 |
| IngrezzaValbenazine Tosylate | 13 | $130,621 |
| AristadaAripiprazole Lauroxil | 37 | $97,020 |
| AuvelityDextromethorphan Hbr/Bupropion | 82 | $66,592 |
| TrintellixVortioxetine Hydrobromide | 108 | $57,425 |
| UzedyRisperidone | 19 | $36,997 |
| VraylarCariprazine Hcl | 21 | $29,808 |
| QuviviqDaridorexant Hcl | 55 | $27,022 |
| Abilify MaintenaAripiprazole | 13 | $25,267 |
| DayvigoLemborexant | 16 | $5,052 |
| Aripiprazole | 38 | $4,316 |
| Lurasidone Hcl | 22 | $4,158 |
| Mirtazapine | 271 | $3,014 |
| Quetiapine Fumarate | 273 | $2,609 |
| Zolpidem Tartrate | 280 | $2,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,121 | $257,243172 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $283 | $130,62113 claims |
| Alkermes, Inc.Aristada | $1,440 | $97,02037 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,335 | $66,59282 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $137 | $57,425108 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $1,892 | $36,99719 claims |
| AbbVieVraylar | $1,561 | $29,80821 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $212 | $27,02255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Flushing
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
- Vera ImperialeAlbany$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.